Cargando…

Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report

Primary peritoneal clear cell carcinoma (PP‐CCC), which is a rare tumor with poor prognosis, is typically managed with surgery and/or chemotherapy. We present a unique treatment approach for a patient with a pelvic PP‐CCC, consisting of postchemotherapy intensity‐modulated radiation therapy (IMRT) f...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Skyler B., Prisciandaro, Joann I., Zhou, Jessica, Hadley, Scott W., Reynolds, R. Kevin, Jolly, Shruti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711230/
https://www.ncbi.nlm.nih.gov/pubmed/24423851
http://dx.doi.org/10.1120/jacmp.v15i1.4520
_version_ 1783283038052941824
author Johnson, Skyler B.
Prisciandaro, Joann I.
Zhou, Jessica
Hadley, Scott W.
Reynolds, R. Kevin
Jolly, Shruti
author_facet Johnson, Skyler B.
Prisciandaro, Joann I.
Zhou, Jessica
Hadley, Scott W.
Reynolds, R. Kevin
Jolly, Shruti
author_sort Johnson, Skyler B.
collection PubMed
description Primary peritoneal clear cell carcinoma (PP‐CCC), which is a rare tumor with poor prognosis, is typically managed with surgery and/or chemotherapy. We present a unique treatment approach for a patient with a pelvic PP‐CCC, consisting of postchemotherapy intensity‐modulated radiation therapy (IMRT) followed by interstitial high‐dose–rate (HDR) brachytherapy. A 54‐year‐old female with an inoperable pelvic‐supravaginal 5.6 cm T3N0M0 PP‐CCC tumor underwent treatment with 6 cycles of carboplatin and taxol chemotherapy. Postchemotherapy PET/CT scan revealed a residual 3.3 cm tumor. The patient underwent CT and MR planning simulation, and was treated with 50 Gy to the primary tumor and 45 Gy to the pelvis including the pelvic lymph nodes, using IMRT to spare bowel. Subsequently, the patient was treated with an interstitial HDR brachytherapy implant, planned using both CT and MR scans. A total dose of 15 Gy in 5 Gy fractions over two days was delivered with Ir‐192 HDR brachytherapy. The total prescribed equivalent 2 Gy dose (EQD2) to the HDR planning target volume (PTV) from both the EBRT and HDR treatments ranged between 63 and [Formula: see text] due to differential dosing of the primary and pelvic targets. The patient tolerated radiotherapy well, except for mild diarrhea not requiring medication. There was no patient‐reported acute toxicity one month following the radiotherapy course. At four months following adjuvant radiation therapy, the patient had near complete resolution of local tumor on PET/CT without any radiation‐associated toxicity. However, the patient was noted to have metastatic disease outside of the radiation field, specifically lesions in the liver and bone. This case report illustrates the feasibility of the treatment of a pelvic PP‐CCC with IMRT followed by interstitial HDR brachytherapy boost, which resulted in near complete local tumor response without significant morbidity. PACS number: 87.55.‐x
format Online
Article
Text
id pubmed-5711230
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57112302018-04-02 Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report Johnson, Skyler B. Prisciandaro, Joann I. Zhou, Jessica Hadley, Scott W. Reynolds, R. Kevin Jolly, Shruti J Appl Clin Med Phys Radiation Oncology Physics Primary peritoneal clear cell carcinoma (PP‐CCC), which is a rare tumor with poor prognosis, is typically managed with surgery and/or chemotherapy. We present a unique treatment approach for a patient with a pelvic PP‐CCC, consisting of postchemotherapy intensity‐modulated radiation therapy (IMRT) followed by interstitial high‐dose–rate (HDR) brachytherapy. A 54‐year‐old female with an inoperable pelvic‐supravaginal 5.6 cm T3N0M0 PP‐CCC tumor underwent treatment with 6 cycles of carboplatin and taxol chemotherapy. Postchemotherapy PET/CT scan revealed a residual 3.3 cm tumor. The patient underwent CT and MR planning simulation, and was treated with 50 Gy to the primary tumor and 45 Gy to the pelvis including the pelvic lymph nodes, using IMRT to spare bowel. Subsequently, the patient was treated with an interstitial HDR brachytherapy implant, planned using both CT and MR scans. A total dose of 15 Gy in 5 Gy fractions over two days was delivered with Ir‐192 HDR brachytherapy. The total prescribed equivalent 2 Gy dose (EQD2) to the HDR planning target volume (PTV) from both the EBRT and HDR treatments ranged between 63 and [Formula: see text] due to differential dosing of the primary and pelvic targets. The patient tolerated radiotherapy well, except for mild diarrhea not requiring medication. There was no patient‐reported acute toxicity one month following the radiotherapy course. At four months following adjuvant radiation therapy, the patient had near complete resolution of local tumor on PET/CT without any radiation‐associated toxicity. However, the patient was noted to have metastatic disease outside of the radiation field, specifically lesions in the liver and bone. This case report illustrates the feasibility of the treatment of a pelvic PP‐CCC with IMRT followed by interstitial HDR brachytherapy boost, which resulted in near complete local tumor response without significant morbidity. PACS number: 87.55.‐x John Wiley and Sons Inc. 2014-01-06 /pmc/articles/PMC5711230/ /pubmed/24423851 http://dx.doi.org/10.1120/jacmp.v15i1.4520 Text en © 2014 The Authors. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Johnson, Skyler B.
Prisciandaro, Joann I.
Zhou, Jessica
Hadley, Scott W.
Reynolds, R. Kevin
Jolly, Shruti
Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
title Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
title_full Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
title_fullStr Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
title_full_unstemmed Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
title_short Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
title_sort primary peritoneal clear cell carcinoma treated with imrt and interstitial hdr brachytherapy: a case report
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711230/
https://www.ncbi.nlm.nih.gov/pubmed/24423851
http://dx.doi.org/10.1120/jacmp.v15i1.4520
work_keys_str_mv AT johnsonskylerb primaryperitonealclearcellcarcinomatreatedwithimrtandinterstitialhdrbrachytherapyacasereport
AT prisciandarojoanni primaryperitonealclearcellcarcinomatreatedwithimrtandinterstitialhdrbrachytherapyacasereport
AT zhoujessica primaryperitonealclearcellcarcinomatreatedwithimrtandinterstitialhdrbrachytherapyacasereport
AT hadleyscottw primaryperitonealclearcellcarcinomatreatedwithimrtandinterstitialhdrbrachytherapyacasereport
AT reynoldsrkevin primaryperitonealclearcellcarcinomatreatedwithimrtandinterstitialhdrbrachytherapyacasereport
AT jollyshruti primaryperitonealclearcellcarcinomatreatedwithimrtandinterstitialhdrbrachytherapyacasereport